▁British 8.59375
▁Bi 8.046875
ote 1.81640625
ch 0.12213134765625
' 5.16796875
s 0.00858306884765625
▁Can 5.8984375
cer 0.04095458984375
▁D 1.435546875
rug 0.01163482666015625
▁Sh 3.03515625
ows 0.058746337890625
▁Promise 0.8701171875
, 3.509765625
▁But 1.478515625
▁Anal 5.65234375
yst 0.00507354736328125
s 0.2244873046875
▁Ur 4.67578125
ge 0.00576019287109375
▁Ca 0.18701171875
ution 0.00024330615997314453
<0x0A> 0.11065673828125
In 4.3984375
▁a 2.005859375
▁land 5.28515625
mark 0.01351165771484375
▁development 3.404296875
▁in 1.9521484375
▁the 0.50390625
▁field 2.296875
▁of 0.03594970703125
▁cancer 0.52392578125
▁treatment 0.88818359375
, 0.05963134765625
▁British 1.5
▁bi 0.404541015625
ote 0.0250244140625
chn 1.4072265625
ology 0.0030975341796875
▁company 0.5947265625
, 2.388671875
▁Bi 2.86328125
ote 4.01953125
ch 0.56201171875
▁UK 5.5859375
, 0.486328125
▁has 0.91455078125
▁revealed 3.9609375
▁prom 2.775390625
ising 0.0006070137023925781
▁results 0.44091796875
▁in 2.490234375
▁the 1.498046875
▁early 2.267578125
▁stages 0.9501953125
▁of 0.00965118408203125
▁testing 2.126953125
▁for 1.4521484375
▁their 2.794921875
▁innov 4.40234375
ative 0.00498199462890625
▁cancer 1.1494140625
▁drug 0.320556640625
. 1.0517578125
▁While 3.73828125
▁this 3.75
▁news 1.544921875
▁has 1.0634765625
▁spark 3.07421875
ed 0.00015473365783691406
▁hope 1.6591796875
▁among 1.1640625
▁patients 1.431640625
▁and 0.1612548828125
▁medical 1.6201171875
▁profession 0.241455078125
als 0.0008797645568847656
▁al 0.376220703125
ike 2.6106834411621094e-05
, 0.01654052734375
▁industry 3.73046875
▁anal 0.315673828125
yst 0.0005512237548828125
s 0.0033512115478515625
▁are 0.71533203125
▁ur 0.4921875
ging 0.0001800060272216797
▁ca 0.0085296630859375
ution 9.393692016601562e-05
▁as 3.0390625
▁the 0.75244140625
▁drug 0.828125
' 3.328125
s 0.00014638900756835938
▁potential 2.791015625
▁benefits 2.15625
▁must 1.9814453125
▁be 0.41015625
▁bal 2.029296875
anced 0.00054931640625
▁with 1.685546875
▁a 3.91796875
▁thorough 1.541015625
▁evaluation 2.197265625
▁of 0.0143890380859375
▁its 0.96484375
▁safety 1.982421875
▁and 0.44482421875
▁effic 0.386962890625
acy 0.00023233890533447266
. 0.1878662109375
<0x0A> 0.100341796875
The 0.64599609375
▁experimental 4.0078125
▁drug 0.42333984375
, 0.1697998046875
▁currently 4.328125
▁named 3.42578125
▁B 0.9365234375
TX 3.615234375
- 0.4462890625
1 1.2998046875
2 2.3984375
3 1.171875
, 0.927734375
▁targets 4.52734375
▁cancer 2.73828125
▁cells 0.1776123046875
▁using 4.421875
▁a 0.1259765625
▁novel 1.1806640625
▁mechanism 0.4892578125
▁that 1.0537109375
▁promises 7.71484375
▁both 6.60546875
▁increased 2.404296875
▁effect 1.9375
iveness 0.0013275146484375
▁and 0.022857666015625
▁reduced 0.5380859375
▁side 0.1671142578125
▁effects 0.040130615234375
▁compared 0.54248046875
▁to 0.0169219970703125
▁traditional 2.265625
▁treat 1.0048828125
ments 1.3232231140136719e-05
. 0.024658203125
▁Initial 4.62890625
▁tri 1.1591796875
als 3.337860107421875e-05
▁conducted 2.826171875
▁on 0.64306640625
▁a 3.34765625
▁small 0.0489501953125
▁sample 2.51953125
▁size 1.2275390625
▁indicate 4.98046875
▁that 0.135009765625
▁B 1.55078125
TX 0.000583648681640625
- 0.00051116943359375
1 0.0007381439208984375
2 0.00015652179718017578
3 0.00078582763671875
▁shows 3.29296875
▁remarkable 4.10546875
▁potential 1.8173828125
▁in 0.55859375
▁in 2.3359375
hib 0.0009598731994628906
iting 0.0005249977111816406
▁the 0.58447265625
▁growth 0.0631103515625
▁of 0.2242431640625
▁various 3.078125
▁types 0.452392578125
▁of 0.0005736351013183594
▁cancer 0.191650390625
▁cells 0.8671875
, 0.712890625
▁providing 6.171875
▁a 1.4931640625
▁g 1.7265625
lim 0.10174560546875
mer 1.633167266845703e-05
▁of 0.0001266002655029297
▁hope 0.00313568115234375
▁for 0.257080078125
▁patients 0.64013671875
▁currently 4.8828125
▁fighting 4.48828125
▁the 0.2763671875
▁disease 0.05975341796875
. 0.0062103271484375
<0x0A> 0.054412841796875
Dr 5.69921875
. 0.0745849609375
▁Emma 5.69921875
▁Davis 5.21875
, 0.021148681640625
▁lead 1.5166015625
▁research 0.2452392578125
er 0.003269195556640625
▁at 1.150390625
▁Bi 0.07171630859375
ote 0.0003421306610107422
ch 0.0033931732177734375
▁UK 0.003391265869140625
, 0.10205078125
▁expressed 1.8779296875
▁c 4.96484375
aut 0.000507354736328125
ious 0.0003261566162109375
▁optim 0.0186309814453125
ism 0.0001233816146850586
▁about 0.65771484375
▁the 0.0202789306640625
▁pre 4.140625
lim 0.0200347900390625
inary 1.9311904907226562e-05
▁results 0.57177734375
, 0.88671875
▁highlight 3.33203125
ing 0.00021326541900634766
▁that 1.8505859375
▁B 3.634765625
TX 0.00030303001403808594
- 0.0008673667907714844
1 0.0005025863647460938
2 0.00013518333435058594
3 0.0005345344543457031
▁has 1.14453125
▁shown 1.2421875
▁encourag 3.673828125
ing 0.00023829936981201172
▁out 4.46875
comes 0.00019299983978271484
▁in 0.28662109375
▁vit 4.94921875
ro 0.00022590160369873047
▁and 0.37451171875
▁in 0.2171630859375
▁animal 2.55078125
▁models 0.63330078125
. 0.34326171875
▁However 1.0537109375
, 0.00011217594146728516
▁she 0.19677734375
▁emphas 0.77197265625
ized 0.04766845703125
▁the 1.6767578125
▁need 0.437255859375
▁for 0.04644775390625
▁extensive 3.935546875
▁human 3.873046875
▁tri 0.45263671875
als 2.562999725341797e-05
▁to 0.767578125
▁truly 5.984375
▁as 4.12109375
certain 0.00020992755889892578
▁its 2.5703125
▁effect 2.171875
iveness 0.002655029296875
▁and 0.411376953125
▁potential 3.123046875
▁side 0.8623046875
▁effects 0.0093536376953125
. 0.30078125
▁Dr 4.875
. 0.0015897750854492188
▁Davis 0.0170135498046875
▁stated 2.71875
, 1.017578125
▁" 0.12158203125
Wh 1.076171875
ile 0.0019311904907226562
▁we 1.1171875
▁are 0.185302734375
▁encourag 1.0419921875
ed 4.208087921142578e-05
▁by 0.0009026527404785156
▁these 1.52734375
▁early 0.9111328125
▁find 0.802734375
ings 3.337860107421875e-06
, 0.00998687744140625
▁it 1.466796875
▁is 0.07318115234375
▁imper 1.6962890625
ative 1.7762184143066406e-05
▁to 2.876953125
▁conduct 0.447021484375
▁rig 1.4541015625
orous 0.00067138671875
▁clin 0.4697265625
ical 3.9458274841308594e-05
▁tri 0.045623779296875
als 8.344650268554688e-07
▁and 3.419921875
▁assess 3.15625
▁the 0.225341796875
▁drug 0.60986328125
' 0.0249786376953125
s 5.5789947509765625e-05
▁safety 0.29833984375
▁and 0.1942138671875
▁effic 0.059356689453125
acy 8.940696716308594e-06
▁in 0.64697265625
▁larger 1.2275390625
▁patient 0.68408203125
▁populations 0.08746337890625
." 2.021484375
<0x0A> 0.0184173583984375
As 3.45703125
▁news 3.287109375
▁of 0.0190887451171875
▁this 3.46484375
▁break 2.42578125
through 2.2292137145996094e-05
▁spread 0.5537109375
, 2.0078125
▁invest 2.322265625
ors 0.06683349609375
▁and 2.015625
▁medical 3.5546875
▁profession 0.25
als 1.2636184692382812e-05
▁al 0.26318359375
ike 3.5762786865234375e-06
▁have 1.287109375
▁become 4.17578125
▁intr 4.80078125
igu 0.0005626678466796875
ed 1.728534698486328e-05
, 2.462890625
▁driving 3.779296875
▁up 0.513671875
▁the 0.34423828125
▁value 2.09375
▁of 0.0008711814880371094
▁Bi 0.1644287109375
ote 0.00036907196044921875
ch 0.000732421875
▁UK 0.0139007568359375
▁stock 2.876953125
s 1.1669921875
. 0.42529296875
▁However 0.744140625
, 8.547306060791016e-05
▁industry 0.9013671875
▁anal 0.236328125
yst 0.0001049041748046875
s 0.017242431640625
▁are 1.1865234375
▁w 4.515625
ary 0.0001989603042602539
▁of 0.12115478515625
▁prem 4.86328125
ature 7.331371307373047e-05
▁ex 3.271484375
uber 0.00601959228515625
ance 0.00019979476928710938
, 0.3056640625
▁rem 2.85546875
inding 0.00067138671875
▁st 4.5859375
ake 9.679794311523438e-05
hold 0.00010669231414794922
ers 2.5033950805664062e-06
▁of 1.912109375
▁the 0.032958984375
▁significant 4.76953125
▁challeng 1.962890625
es 1.239776611328125e-05
▁that 0.72900390625
▁lie 0.91748046875
▁ahead 0.0007758140563964844
▁in 1.671875
▁bringing 0.86083984375
▁B 1.5693359375
TX 0.00010132789611816406
- 0.0003120899200439453
1 0.00043201446533203125
2 0.0001010894775390625
3 0.00022172927856445312
▁to 0.0287322998046875
▁market 0.1278076171875
. 0.03924560546875
<0x0A> 0.6484375
One 1.62109375
▁of 0.994140625
▁the 0.008331298828125
▁major 1.8037109375
▁hur 1.0859375
d 3.5762786865234375e-07
les 3.886222839355469e-05
▁the 4.8203125
▁drug 0.630859375
▁must 1.080078125
▁overcome 0.13818359375
▁is 0.0269012451171875
▁the 0.81591796875
▁rig 2.728515625
orous 0.004848480224609375
▁testing 3.365234375
▁and 0.5546875
▁regul 1.1640625
atory 1.2874603271484375e-05
▁appro 0.1868896484375
val 3.933906555175781e-06
▁process 0.1324462890625
▁for 6.0
▁ph 2.658203125
arma 0.0017995834350585938
ce 0.0002846717834472656
ut 2.9802322387695312e-06
ical 2.2530555725097656e-05
▁products 0.94384765625
. 0.20654296875
▁The 1.9833984375
▁drug 2.015625
▁must 0.65966796875
▁pass 1.822265625
▁several 2.412109375
▁stages 1.2392578125
▁of 0.0159912109375
▁clin 0.79736328125
ical 5.340576171875e-05
▁tri 0.0220489501953125
als 5.364418029785156e-06
▁before 2.333984375
▁it 0.370849609375
▁can 0.06793212890625
▁be 0.13671875
▁de 3.083984375
emed 8.177757263183594e-05
▁safe 0.027069091796875
▁and 0.0723876953125
▁effective 0.0052490234375
▁for 0.403076171875
▁w 1.52734375
ides 1.9431114196777344e-05
p 0.0003478527069091797
read 4.1961669921875e-05
▁use 0.01415252685546875
. 0.394775390625
▁These 3.37890625
▁tri 0.10113525390625
als 7.987022399902344e-06
▁are 1.634765625
▁essential 3.33984375
▁to 0.7373046875
▁determine 2.357421875
▁the 0.2332763671875
▁drug 0.171142578125
' 0.0009622573852539062
s 2.777576446533203e-05
▁optimal 3.732421875
▁dos 0.287353515625
age 0.0692138671875
, 0.244873046875
▁potential 1.5869140625
▁side 0.0753173828125
▁effects 0.0011119842529296875
, 0.012298583984375
▁and 0.004486083984375
▁overall 1.904296875
▁impact 4.1953125
▁on 0.01947021484375
▁different 5.37109375
▁cancer 2.12109375
▁types 0.0693359375
. 0.09906005859375
▁The 3.60546875
▁length 2.833984375
▁and 1.1025390625
▁complexity 0.697265625
▁of 0.0001628398895263672
▁this 1.22265625
▁process 0.046051025390625
, 3.623046875
▁combined 1.6357421875
▁with 2.777576446533203e-05
▁the 0.082275390625
▁possibility 7.328125
▁of 0.014404296875
▁un 1.744140625
for 0.1710205078125
ese 7.867813110351562e-06
en 0.0009860992431640625
▁comp 1.38671875
lications 0.0001468658447265625
, 0.203125
▁pose 4.50390625
▁considerable 4.53515625
▁ris 0.736328125
ks -0.0
▁to 0.99951171875
▁the 0.9326171875
▁drug 1.212890625
' 0.0199127197265625
s 1.0848045349121094e-05
▁development 1.1767578125
. 0.580078125
<0x0A> 0.035400390625
F 3.361328125
ur 0.0107269287109375
ther 2.86102294921875e-05
more 0.043670654296875
, 2.7298927307128906e-05
▁ske 7.26171875
pt 0.486328125
ics 0.0254364013671875
▁argue 2.0546875
▁that 0.0015096664428710938
▁even 2.892578125
▁if 0.0222320556640625
▁the 0.84814453125
▁drug 0.06005859375
▁passes 1.6435546875
▁all 0.7958984375
▁necessary 1.3212890625
▁testing 2.365234375
▁and 0.697265625
▁appro 2.216796875
val 8.809566497802734e-05
▁stages 3.162109375
, 0.017333984375
▁the 2.7578125
▁market 2.0859375
▁for 0.431884765625
▁cancer 0.1905517578125
▁treatment 1.8173828125
▁is 0.8388671875
▁highly 1.7783203125
▁compet 0.1385498046875
itive 1.0132789611816406e-05
▁and 1.5673828125
▁domin 2.0234375
ated 4.76837158203125e-05
▁by 0.00012981891632080078
▁established 0.275146484375
▁ph 1.9990234375
arma 0.00034236907958984375
ce 0.004642486572265625
ut 3.6954879760742188e-06
ical 4.291534423828125e-06
▁gi 1.5986328125
ants 1.1920928955078125e-07
. 0.26806640625
▁Bi 1.4365234375
ote 0.00035881996154785156
ch 0.0064697265625
▁UK 0.007755279541015625
▁would 3.69921875
▁have 1.458984375
▁to 0.01025390625
▁navigate 2.447265625
▁a 1.29296875
▁complex 2.154296875
▁landscape 1.9462890625
▁to 2.486328125
▁secure 1.95703125
▁market 3.521484375
▁share 0.2242431640625
▁and 0.42919921875
▁face 7.56640625
▁fier 2.892578125
ce 0.00011157989501953125
▁competition 0.024169921875
▁from 0.1259765625
▁big 5.09765625
▁industry 4.55859375
▁players 0.03564453125
, 2.599609375
▁some 3.802734375
▁of 0.14501953125
▁whom 0.77880859375
▁are 2.10546875
▁invest 3.873046875
ing 0.007572174072265625
▁significant 2.759765625
▁resources 0.176513671875
▁in 0.435302734375
▁similar 3.361328125
▁research 1.318359375
. 0.7568359375
<0x0A> 0.1920166015625
Anal 5.5234375
yst 0.00739288330078125
s 0.0174407958984375
▁have 2.48046875
▁also 1.2763671875
▁raised 1.1806640625
▁concerns 0.0787353515625
▁about 0.11883544921875
▁the 0.11749267578125
▁potential 1.1396484375
▁impact 2.470703125
▁on 2.068359375
▁patients 1.7568359375
▁who 3.0
▁might 4.22265625
▁pin 12.2734375
▁all 4.9609375
▁their 0.103759765625
▁hopes 0.056884765625
▁on 0.046234130859375
▁a 1.4482421875
▁drug 2.3828125
▁that 0.1729736328125
▁still 4.2109375
▁has 1.26953125
▁a 0.53125
▁long 0.0221099853515625
▁path 6.06640625
▁to 0.37255859375
▁appro 1.15625
val 4.673004150390625e-05
. 0.72705078125
▁The 2.3203125
▁emot 4.4765625
ional 0.0280609130859375
▁to 1.9130859375
ll 0.0009560585021972656
▁of 0.6337890625
▁dashed 9.6875
▁expect 0.337646484375
ations 1.2755393981933594e-05
▁can 1.755859375
▁be 0.078125
▁dev 1.0478515625
ast 1.0728836059570312e-05
ating 0.0004076957702636719
▁for 1.044921875
▁patients 0.94775390625
▁and 0.4501953125
▁their 0.10821533203125
▁families 0.2666015625
. 2.404296875
▁Exper 5.79296875
ts 0.044281005859375
▁stress 3.490234375
▁the 0.71240234375
▁importance 0.317626953125
▁of 0.00048732757568359375
▁maintain 2.275390625
ing 4.649162292480469e-05
▁real 0.382568359375
istic 0.0168914794921875
▁expect 0.0209197998046875
ations 2.5033950805664062e-06
▁throughout 5.16796875
▁the 0.054718017578125
▁drug 0.7861328125
▁development 0.591796875
▁process 0.0265655517578125
, 1.40234375
▁while 2.54296875
▁continu 3.876953125
ing 0.04437255859375
▁to 0.006984710693359375
▁investigate 5.60546875
▁and 1.359375
▁invest 2.21875
▁in 0.004291534423828125
▁alternative 2.169921875
▁treatment 1.283203125
▁options 0.0450439453125
. 0.19091796875
<0x0A> 0.01515960693359375
Dr 4.8984375
. 0.0011959075927734375
▁Am 6.953125
elia 1.8603515625
▁Thompson 5.1484375
, 0.0269012451171875
▁an 2.291015625
▁on 0.352294921875
colog 0.1826171875
ist 0.0011968612670898438
▁at 0.26220703125
▁a 1.4111328125
▁leading 0.55810546875
▁cancer 0.52587890625
▁center 1.2021484375
, 0.83740234375
▁advis 5.85546875
es 0.0004723072052001953
▁ca 0.9541015625
ution 1.609325408935547e-05
▁and 2.091796875
▁p 2.0625
atience 0.06964111328125
. 1.751953125
▁" 0.876953125
Wh 0.69775390625
ile 2.300739288330078e-05
▁the 1.8232421875
▁initial 2.0078125
▁results 0.55859375
▁are 0.93408203125
▁indeed 5.65625
▁prom 0.279296875
ising 2.2530555725097656e-05
, 0.021484375
▁it 0.826171875
▁is 0.410400390625
▁essential 1.544921875
▁for 4.26953125
▁patients 1.47265625
▁and 0.54931640625
▁the 2.482421875
▁medical 0.65087890625
▁community 0.006267547607421875
▁to 0.08514404296875
▁exercise 3.3203125
▁rest 1.4951171875
raint 0.0003247261047363281
▁until 2.73828125
▁the 0.79736328125
▁drug 0.16015625
' 2.728515625
s 4.076957702636719e-05
▁safety 1.076171875
▁and 0.034149169921875
▁effic 0.1180419921875
acy 2.6226043701171875e-06
▁have 0.76806640625
▁been 0.0025310516357421875
▁proven 3.3046875
▁in 0.7783203125
▁rig 2.923828125
orous 0.0034732818603515625
▁clin 0.2279052734375
ical 9.059906005859375e-06
▁tri 0.00858306884765625
als 1.3113021850585938e-06
," 1.275390625
▁she 0.078857421875
▁emphas 1.9931640625
ized 0.53759765625
. 0.023406982421875
▁" 0.93798828125
There 3.86328125
▁have 3.509765625
▁been 0.004436492919921875
▁instances 4.25
▁in 0.599609375
▁the 0.018646240234375
▁past 0.002605438232421875
▁where 0.1265869140625
▁initial 4.48828125
▁excitement 2.45703125
▁around 2.65625
▁potential 3.767578125
▁break 1.1376953125
through 9.417533874511719e-06
s 0.155517578125
▁has 1.03515625
▁not 5.67578125
▁been 2.298828125
▁translated 4.33203125
▁into 0.007076263427734375
▁real 2.701171875
- 0.292724609375
world 0.06817626953125
▁success 3.12890625
." 1.611328125
<0x0A> 0.047515869140625
U 4.46875
lt 0.03948974609375
imately 0.00010526180267333984
, 9.310245513916016e-05
▁Bi 3.10546875
ote 6.592273712158203e-05
ch 0.0005078315734863281
▁UK 0.0020599365234375
' 0.54638671875
s 7.867813110351562e-05
▁B 1.642578125
TX 0.00019681453704833984
- 0.000629425048828125
1 0.00030875205993652344
2 8.153915405273438e-05
3 0.00020694732666015625
▁has 2.751953125
▁shown 1.423828125
▁great 1.8115234375
▁promise 0.393798828125
▁in 0.4521484375
▁the 1.3115234375
▁early 0.28173828125
▁stages 0.0222625732421875
▁of 0.027862548828125
▁testing 0.61328125
, 0.330078125
▁offering 3.046875
▁a 2.2421875
▁g 0.630859375
lim 0.07208251953125
mer 8.940696716308594e-06
▁of 8.893013000488281e-05
▁hope 0.0005240440368652344
▁for 0.372802734375
▁cancer 1.642578125
▁patients 0.00516510009765625
▁eager 7.5
ly 0.642578125
▁await 0.300048828125
ing 0.0002830028533935547
▁new 0.83642578125
▁treatment 0.52587890625
▁options 0.00798797607421875
. 0.002780914306640625
▁However 0.34912109375
, 4.506111145019531e-05
▁careful 7.2734375
▁consideration 1.333984375
▁must 1.37890625
▁be 0.0218048095703125
▁given 0.1407470703125
▁to 0.00795745849609375
▁the 0.1116943359375
▁need 7.95703125
▁for 0.03265380859375
▁extensive 1.0283203125
▁clin 1.046875
ical 3.075599670410156e-05
▁tri 0.043212890625
als 3.647804260253906e-05
, 0.9677734375
▁regul 0.79296875
atory 1.4066696166992188e-05
▁appro 0.08807373046875
val 5.245208740234375e-06
, 0.6689453125
▁and 0.09783935546875
▁the 1.3125
▁challeng 2.57421875
es 0.434326171875
▁pos 2.267578125
ed 1.0013580322265625e-05
▁by 0.0022182464599609375
▁the 1.4951171875
▁compet 0.7001953125
itive 0.00010311603546142578
▁market 0.90771484375
. 1.2744140625
▁While 1.642578125
▁the 0.880859375
▁road 2.716796875
▁ahead 0.38671875
▁remains 3.21875
▁uncertain 1.609375
, 0.013519287109375
▁this 4.01953125
▁break 1.9697265625
through 3.337860107421875e-05
▁represents 1.6611328125
▁a 0.2978515625
▁significant 0.294189453125
▁step 0.193603515625
▁forward 0.0543212890625
▁in 0.034210205078125
▁the 0.05303955078125
▁fight 0.57177734375
▁against 0.0007624626159667969
▁cancer 0.0548095703125
▁and 1.4248046875
▁provides 3.078125
▁a 1.703125
▁be 3.875
acon 0.0004677772521972656
▁of 0.0004038810729980469
▁hope 0.015838623046875
▁for 0.032257080078125
▁better 11.609375
▁treatment 1.03125
▁options 0.2215576171875
▁in 0.56494140625
▁the 0.005138397216796875
▁future 0.058197021484375
. 0.0064697265625
